News

Expert class ‘Business and Sales Development’ review

On the 18th of March, Iventus and LifeSciences@Work had the honor to host the second expert class of this year.
Expert class ‘Business and Sales Development’ review

You can now express your interest in IPCEI Health!

IPCEI stands for Important Projects of Common European Interest.
You can now express your interest in IPCEI Health!

Een primeur in de geschiedenis van de Nationale Zorginnovatieprijs: Helpsoq wint zowel de vakjury- als de publieksprijs!

De innovatie Helpsoq is unaniem uitgeroepen tot de winnaar van de Nationale Zorginnovatieprijs 2022. Tijdens de uitreiking op het Health Valley Event werd Helpsoq aangekondigd als winnaar van zowel de vakjuryprijs ter waarde van €10.000,- als de publieksprijs ter waarde van €5.000,-. Een unicum in de geschiedenis van deze prijs.
Winner

Venture Challenge Alumnus Bi/ond has closed over $4+ Million in funding to date led by FORWARD.one

Organ-on-a-chip succes with leading European research institutioins fuels Bi/ond Investment.
Research

Venture Challenge Alumnus TargED raises €39 million in a series A investment round

TargED Biopharmaceuticals raises EUR 39 Million in Series A financing to bring groundbreaking thrombolytic treatment to patients.
Venture Challenge Alumnus TargED raises €39 million in a series A investment round

Pharmaceutical product based on SeraNovo's eutectic formulation enters clinical study

Venture Challenge winner SeraNovo is proud to announce that in December 2021, Carna Biosciences initiated a clinical study with a drug product based on a joint development program with SeraNovo's eutectic formulation technology. 
SeraNovo

Two free slots available for the Paul Janssen Futurelab blended course Clinical Development! 

J&J Pharmaceuticals pays the course fee for 2 graduated biomedical professionals for their participation in the Paul Janssen Futurelab blended course Clinical Development.
Clinical development course

Meet the teams of the Proefdiervrij Venture Challenge 2022

Following the successful first edition in 2021, Stichting Proefdiervrij is organising the second edition of the Proefdiervrij Venture Challenge from February - April 2022. During the Proefdiervrij Venture Challenge, these teams of researchers, are g
Proefdiervrij VC

Venture Challenge Winner Hybridize Enters Agreement for a Direct-acting RNA-based Therapy Against BK Virus

AiCuris and Hybridize Therapeutics enter worldwide license agreement of up to €100M for a direct-acting RNA-based therapy against BK Virus.
Hybridize

Venture Academy 2022

Join the Venture Academy Programme, a three-month programme where you can follow a specialised unlock_ track tailored for the Life Sciences and Health.
Banner